Prostate Cancer Survival Linked to PSA Levels Below 0.2 ng/mL Threshold

A recent real-world study published in CANCER shows that prostate cancer patients who achieve prostate-specific antigen (PSA) levels below 0.2 ng/mL after treatment for metastatic disease experience improved survival outcomes. PSA is a key biomarker used to monitor treatment effectiveness in prostate cancer patients, with lower levels indicating better therapeutic response. This finding provides clinicians and patients with a specific target goal during metastatic prostate cancer treatment, helping guide therapeutic decisions and prognosis discussions. Understanding these PSA thresholds can help patients and healthcare providers assess whether current treatments are working effectively.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: August 10, 2026 at 10:02 AM


